ERX3551607 E-MTAB-7039:Sample 10_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759243 SAMEA5789105 Sample 10_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site neoplasm ERX3551608 E-MTAB-7039:Sample 9_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759244 SAMEA5789106 Sample 9_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site normal tissue adjacent to tumour ERX3551609 E-MTAB-7039:Sample 11_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759245 SAMEA5789107 Sample 11_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site normal tissue adjacent to tumour ERX3551610 E-MTAB-7039:Sample 12_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759246 SAMEA5789108 Sample 12_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site neoplasm ERX3551611 E-MTAB-7039:Sample 1_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759247 SAMEA5789109 Sample 1_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site normal tissue adjacent to tumour ERX3551612 E-MTAB-7039:Sample 2_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759248 SAMEA5789110 Sample 2_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site neoplasm ERX3551613 E-MTAB-7039:Sample 3_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759249 SAMEA5789111 Sample 3_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site normal tissue adjacent to tumour ERX3551614 E-MTAB-7039:Sample 4_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759250 SAMEA5789112 Sample 4_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site neoplasm ERX3551615 E-MTAB-7039:Sample 5_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759251 SAMEA5789113 Sample 5_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site normal tissue adjacent to tumour ERX3551616 E-MTAB-7039:Sample 6_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759252 SAMEA5789114 Sample 6_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site neoplasm ERX3551617 E-MTAB-7039:Sample 7_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759253 SAMEA5789115 Sample 7_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site normal tissue adjacent to tumour ERX3551618 E-MTAB-7039:Sample 8_p ERP117419 PRJEB34507 Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers ERS3759254 SAMEA5789116 Sample 8_p RNA-Seq TRANSCRIPTOMIC RANDOM Patients and tissue collection. Six patients, who underwent type A radical hysterectomy with or without pelvic lymphadenectomy for EC, were enrolled in the present study at the University of Salerno. The study protocol received institutional review board (IRB) approval before the beginning of the study, in accordance with The Code of Ethics of the Declaration of Helsinki, and informed consent was obtained from all patients. From each patient a sample of neoplastic tissue and corresponding normal endometrium were collected, washed and stored at -80° until analysis. The histology of each EC was classified according to World Health Organization criteria, whereas surgical staging followed International Federation of Gynecology and Obstetrics (FIGO) standards. RNA isolation and quality controls. Tissue specimen were disrupted and homogenized using TissueLyser LT (Qiagen, Germany). Total RNA was extracted with miRVana RNA isolation Kit (Thermo Fisher Scientific, MA, USA) according to the manufacturer's protocol. Before use, RNA concentration in each sample was assayed with a NanoDrop ND-2000c (Thermo Fisher Scientific) and its quality assessed with the Agilent 2100 Bioanalyzer using Agilent RNA 6000 nano kit (Agilent Technologies, CA, USA). Briefly, 1 μg of total RNA was used in a library preparation according to the Illumina TruSeq stranded total RNA sample preparation protocol (Illumina, CA, USA). Each library was sequenced on HiSeq 2500 (Illumina) at a concentration of 8pM for 200 cycles plus 7 additional cycles for indexes sequencing in paired-mode (2x100 base pair). Illumina HiSeq 2500 Experimental Factor: sampling site neoplasm